| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 689.12 | 2.4% | 6.1% |
| Total Income | 711.89 | 3.6% | 7.9% |
| Expenditure | 496.10 | 7.2% | 5.9% |
| PBT | 215.80 | 8.8% | 12.8% |
| Net Profit | 162.66 | 8.3% | 14.7% |
| OPM | 31.13% | 0.57pp | 0.58pp |
| NPM | 22.85% | 0.97pp | 1.34pp |
| EPS | 13.23 | 8.0% | 14.3% |
Alivus Life Sciences FY26 Revenue Up 6.9% YoY to ₹25,518 Mn
14 May 2026 · 14 May, 8:12 pm
Summary
Alivus Life Sciences Limited announced strong financial results for the quarter and year ended March 31, 2026, with FY26 revenue from operations growing 6.9% year-on-year to ₹2,551.8 crore. Profit after tax (PAT) for the full year increased by 16.2% to ₹564.5 crore, while EBITDA surged 19.6% to ₹857.7 crore, driven by robust 33.6% EBITDA margins, exceeding guidance. Management highlighted a clear improvement in operating performance, strong growth in the non-GPL business, and a successful turnaround in the CDMO segment. For FY27, the company remains confident of delivering high single-digit revenue growth and sustaining margins above 30%, supported by improving operating leverage and new product contributions.
Key Highlights
- 1
Alivus Life Sciences recorded a Revenue from operations of ₹2,551.8 crore for FY26, marking a robust growth of 6.9% year-on-year.
- 2
Profit After Tax (PAT) for FY26 increased by 16.2% year-on-year to ₹564.5 crore, with PAT margins improving by 180 bps to 22.1%.
- 3
EBITDA for FY26 grew significantly by 19.6% year-on-year to ₹857.7 crore, achieving EBITDA margins of 33.6%, up 360 bps.
- 4
The company reported strong Q4FY26 performance with Revenue from operations at ₹689.1 crore, up 6.1% year-on-year, and EBITDA at ₹237.3 crore, growing 13.8% year-on-year.
- 5
The CDMO business delivered a planned turnaround in the second half, closing FY26 with an impressive 18% year-on-year growth.
- 6
Alivus generated strong free cash flow of ₹259.0 crore during FY26, contributing to Cash and Cash Equivalents (including short term investments) of ₹782.4 crore as of March 31, 2026.
- 7
New strategic initiatives include the acquisition of land in Taloja, Navi Mumbai, to establish a state-of-the-art R&D centre, with construction already commenced.
Management Comments
Dr. Yasir Rawjee
The past two years under Nirma's ownership have been deeply fulfilling — a period of transition and evolution that has strengthened the foundation of the business and positioned us decisively for the next phase of sustainable growth. Coming to our results, FY26 reflected a clear improvement in our operating performance. Revenue grew 6.9% year-on-year, supported by growth in non-GPL business of 13%, which resulted in EBITDA growth of 19.6%. Encouragingly, the CDMO business delivered the turnaround we had planned in the second half, closing the year with 18% YoY growth. We also witnessed healthy momentum across key geographies like India, Europe, ROW, Japan and LATAM, while the GPL business de-grew by 4.9%. For FY27, we remain confident of delivering high single-digit revenue growth, with margins sustained above 30%, supported by improving operating leverage and a rising contribution from new products.
Tushar Mistry
We continued our strong growth momentum in Q4FY26, delivering 6.1% year-on-year revenue growth. We ended FY26 with 6.9% growth. The performance was broad-based, with contributions from almost all regions. At Alivus, we remain focused on profitable growth, reflected in the improvement in both, our Gross and EBITDA margins during the quarter. For the full year, we reported EBITDA margins of 33.6%, exceeding our guided range of 30–32%, driven by a favourable product mix and disciplined control over operating expenses. The year has ended with strong operating cash flows, providing us ample flexibility to support our growth initiatives while maintaining a healthy, debt-free balance sheet.
Informational and educational content only. Not investment advice.